Cargando…
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
AIM: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). PATIENTS & METHODS: Systematically reviewed multiple databases through 22 July 2021....
Autores principales: | Miller, Sally D, Lozano-Ortega, Greta, Mutebi, Alex, Briggs, Owanate, Sail, Kavita, Elliott, Brian, Kalsekar, Anupama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288944/ https://www.ncbi.nlm.nih.gov/pubmed/36417238 http://dx.doi.org/10.2217/cer-2022-0146 |
Ejemplares similares
-
P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Crombie, Jennifer, et al.
Publicado: (2023) -
P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023) -
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
por: Galaznik, Aaron, et al.
Publicado: (2018) -
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022) -
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell
Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)